Our latest CAMO-Net project in the UK has begun, as blood samples have been taken from the first participant on the DATA TDM project.
DATA TDM, or Analysis of Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment to Assess the Potential Role of Therapeutic Drug Monitoring in UK Infection Management, sheds light on a promising technique to optimise the use of antibiotics.
With more than 320 participants, this three year study will investigate the intricacies of antibiotic dosing, aiming to revolutionise infection management practices across the UK and beyond.
Optimising the use of existing antibiotics is an essential aspect of combating infectious diseases and tackling antimicrobial resistance (AMR).
The primary aim of DATA TDM is to assess the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust (ICHNT). With secondary objectives including evaluating co-administered non-beta-lactam antibiotics, exploring dynamic biomarker patterns, and supporting the development of new techniques, this comprehensive investigation offers a multifaceted approach to enhancing antimicrobial therapy.
Beta-lactam antibiotics are a type of medication used to fight bacterial infections. They work by targeting the cell walls of bacteria, which are essential for their survival. These antibiotics disrupt the formation of the bacterial cell wall, causing the bacteria to weaken and die. They’re commonly used to treat a wide range of infections, from minor ear infections to more pneumonia and meningitis. Beta-lactam antibiotics include penicillin, amoxicillin, and cephalosporins.
The rise in infections caused by multidrug-resistant organisms requires innovative strategies, and optimising antibiotic use is an essential factor in minimising the risk of AMR. Personalised care and medicines optimisation, as advocated by the Department of Health and Social Care in the UK, underscore the importance of tailoring treatment approaches to individual patients.
The rationale for the DATA TDM study stems from the existing gaps in pharmaco-epidemiological data regarding antimicrobial dosing outside critical care settings. With thousands of patients managed weekly within the NHS for diverse infections, the study harnesses routinely collected clinical data to observe real-world scenarios. By enrolling a broad range of beta-lactam-treated patients and correlating drug concentration targets with treatment outcomes, the study lays the groundwork for future interventions and clinical trials.
Suzy Williams, Research Nurse at Imperial College London and DATA TDM lead said, “Currently, we give most antimicrobials in a (almost) one-size-fits-all way. However, everyone is different, including how our bodies process and excrete antimicrobials. This can even change for individuals depending on how unwell they are. There is evidence that shows our one-size-fits-all approach means that some people are not treated optimally. With this study, we aim to investigate how well we are currently giving antimicrobials across a range of different patients. With this information, we will then be able to explore new ways of tailoring these antimicrobials, to make sure that we are providing the most optimal care for our patients with infections.”
The DATA TDM study epitomises a paradigm shift in infection management, leveraging the power of therapeutic drug monitoring to optimise antimicrobial therapy. As we delve deeper into the intricate interplay between drug exposure, pharmacodynamics, and clinical outcomes, the DATA TDM study will be an important next step in precision medicine investigation, and will help to address antimicrobial resistance around the world.
